BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after approval of 80mg ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE